We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Comen Medical

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
24 Jan 2022 - 27 Jan 2022

Occlusion Device Supports Oxygenation During Cardiac Arrest

By HospiMedica International staff writers
Posted on 25 Oct 2021
Print article
Image: The NeuRescue occlusion catheter and control unit (Photo courtesy of NeuRescue)
Image: The NeuRescue occlusion catheter and control unit (Photo courtesy of NeuRescue)
A fluoroscopy-free balloon catheter provides temporary occlusion of large blood vessels in sudden cardiac arrest (SCA) patients in order to redirect blood flow to the brain and heart.

The Neurescue (Copenhagen, Denmark) system is composed of a controller and a single-use balloon catheter kit that together provide aortic occlusion--an emergency technique that supercharges blood flow to the heart and brain--within one minute from deployment. The catheter-based device is delivered via the femoral artery, temporarily inflating a soft balloon in the aorta to redirect blood flow towards the upper body. The procedure is performed to provide additional time to control blood loss and bridge patients to additional life-saving treatment options.

The control unit houses patented sensors and automated inflation technology, with an intelligent safety feedback system that helps ensure safe catheter positioning, providing automated filling and feedback in order to prevent over-inflation, rupture, and tissue damage, while monitoring blood pressure throughout. The NeuRescue can thus accomplish immediate resuscitation from SCA, as well as bridge patients to definitive treatments such as extracorporeal membrane oxygenation (ECMO), stents, or pacemakers.

“The increase in blood supply to the heart ensures that many more hearts can be resuscitated,” said Habib Frost, PhD, founder and CEO of Neurescue. “The increased blood supply to the brain protects against brain damage, allowing for more time to treat the underlying cause of the cardiac arrest. This approach can greatly improve the current survival rate.”

“The NeuRescue device represents a significant advancement that could meaningfully improve the survival rates for emergency patients,” said Maham Rahimi, MD, PhD, assistant professor of cardiovascular surgery at Weill Cornell School of Medicine (New York, NY, USA). “The device gives patients suffering traumatic blood loss a longer window of time to receive appropriate medical interventions, which can directly translate to saved lives.”

During SCA, heart function ceases abruptly, and without warning. Without bystander intervention using cardiopulmonary resuscitation (CPR) and automatic defibrillator (AED) devices, survival rate is about 10%. It is important, however, to remember SCA is not a heart attack; heart muscle does not die. It occurs when the heart’s electrical system malfunctions and the heart stops beating, most commonly due to ventricular fibrillation and ventricular tachycardia (VT).

Related Links:

Print article



view channel

J&J Medical Devices Companies Partners with Microsoft to Further Enable its Digital Surgery Solutions

The Johnson & Johnson Medical Devices Companies (JJMDC; New Brunswick, NJ, USA) will collaborate with Microsoft (Redmond, Wash., USA) to further enable and expand JJMDC’s secure and compliant digital... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.